Immunotech Biopharm Ltd
Company Profile
Business description
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
Contact
No.1 Kangding Street
8th Floor, Block 1, Guosheng Technology Park
Beijing Economic-technological Development Area
Beijing100176
CHNT: +86 8610884002
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
173
Stocks News & Analysis
stocks
3 ASX opportunities after earnings season
stocks
Oracle earnings: Solid execution secures revenue target and mitigates investor concerns
stocks
US dividend shares are getting a boost from the HALO trade. Can it last?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,795.80 | 1.00 | 0.01% |
| CAC 40 | 7,911.53 | 72.91 | -0.91% |
| DAX 40 | 23,447.29 | 142.36 | -0.60% |
| Dow JONES (US) | 46,558.47 | 119.38 | -0.26% |
| FTSE 100 | 10,261.15 | 44.00 | -0.43% |
| HKSE | 25,755.53 | 289.93 | 1.14% |
| NASDAQ | 22,105.36 | 206.62 | -0.93% |
| Nikkei 225 | 53,582.29 | 237.32 | -0.44% |
| NZX 50 Index | 13,164.58 | 22.76 | -0.17% |
| S&P 500 | 6,632.19 | 40.43 | -0.61% |
| S&P/ASX 200 | 8,586.00 | 10.40 | 0.12% |
| SSE Composite Index | 4,066.40 | 29.05 | -0.71% |